| Schlüsselwörter:Biologicals,
Arzneimittel, Therapie, Behandlung, Monoklonale
Antikörper, Adalimumab (Humira), Bevacizumab (Avastin®),
Biological, Cetuximab (Erbitux®), Daclizumab (Zenapax®),
Efalizumab (Raptiva®), Infliximab (Remicade®), Natalizumab (Tysabri®),
Omalizumab (Xolair®), Panitumumab (ABX-EGF), Rituximab, MabThera,
Tositumomab (Bexxar®), Trastuzumab (Herceptin), Medikament, Krankheit, Studie, Therapie, Behandlung, Medikament und Studien. |